240 related articles for article (PubMed ID: 9242375)
1. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M
Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375
[TBL] [Abstract][Full Text] [Related]
2. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma.
Iwashita T; Kato M; Murakami H; Asai N; Ishiguro Y; Ito S; Iwata Y; Kawai K; Asai M; Kurokawa K; Kajita H; Takahashi M
Oncogene; 1999 Jul; 18(26):3919-22. PubMed ID: 10445857
[TBL] [Abstract][Full Text] [Related]
3. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
[TBL] [Abstract][Full Text] [Related]
4. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.
Carlomagno F; Salvatore G; Cirafici AM; De Vita G; Melillo RM; de Franciscis V; Billaud M; Fusco A; Santoro M
Cancer Res; 1997 Feb; 57(3):391-5. PubMed ID: 9012462
[TBL] [Abstract][Full Text] [Related]
5. RET activation by germline MEN2A and MEN2B mutations.
Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
[TBL] [Abstract][Full Text] [Related]
6. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance.
Engelmann D; Koczan D; Ricken P; Rimpler U; Pahnke J; Li Z; Pützer BM
Endocr Relat Cancer; 2009 Mar; 16(1):211-24. PubMed ID: 18984779
[TBL] [Abstract][Full Text] [Related]
8. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations.
Rossel M; Pasini A; Chappuis S; Geneste O; Fournier L; Schuffenecker I; Takahashi M; van Grunsven LA; Urdiales JL; Rudkin BB; Lenoir GM; Billaud M
Oncogene; 1997 Jan; 14(3):265-75. PubMed ID: 9018112
[TBL] [Abstract][Full Text] [Related]
9. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.
Chappuis-Flament S; Pasini A; De Vita G; Ségouffin-Cariou C; Fusco A; Attié T; Lenoir GM; Santoro M; Billaud M
Oncogene; 1998 Dec; 17(22):2851-61. PubMed ID: 9879991
[TBL] [Abstract][Full Text] [Related]
10. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.
Michiels FM; Chappuis S; Caillou B; Pasini A; Talbot M; Monier R; Lenoir GM; Feunteun J; Billaud M
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3330-5. PubMed ID: 9096393
[TBL] [Abstract][Full Text] [Related]
11. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
12. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
[TBL] [Abstract][Full Text] [Related]
13. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC.
Eng C; Smith DP; Mulligan LM; Healey CS; Zvelebil MJ; Stonehouse TJ; Ponder MA; Jackson CE; Waterfield MD; Ponder BA
Oncogene; 1995 Feb; 10(3):509-13. PubMed ID: 7845675
[TBL] [Abstract][Full Text] [Related]
14. Germline RET mutations in MEN 2A and FMTC and their detection by simple DNA diagnostic tests.
Xue F; Yu H; Maurer LH; Memoli VA; Nutile-McMenemy N; Schuster MK; Bowden DW; Mao J; Noll WW
Hum Mol Genet; 1994 Apr; 3(4):635-8. PubMed ID: 7915165
[TBL] [Abstract][Full Text] [Related]
15. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
Marsh DJ; Mulligan LM; Eng C
Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
[TBL] [Abstract][Full Text] [Related]
16. Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential.
Cirafici AM; Salvatore G; De Vita G; Carlomagno F; Dathan NA; Visconti R; Melillo RM; Fusco A; Santoro M
Endocrinology; 1997 Apr; 138(4):1450-5. PubMed ID: 9075701
[TBL] [Abstract][Full Text] [Related]
17. C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET.
Reynolds L; Jones K; Winton DJ; Cranston A; Houghton C; Howard L; Ponder BA; Smith DP
Oncogene; 2001 Jul; 20(30):3986-94. PubMed ID: 11494127
[TBL] [Abstract][Full Text] [Related]
18. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway.
Segouffin-Cariou C; Billaud M
J Biol Chem; 2000 Feb; 275(5):3568-76. PubMed ID: 10652352
[TBL] [Abstract][Full Text] [Related]
19. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.
Ito S; Iwashita T; Asai N; Murakami H; Iwata Y; Sobue G; Takahashi M
Cancer Res; 1997 Jul; 57(14):2870-2. PubMed ID: 9230192
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
Donis-Keller H; Dou S; Chi D; Carlson KM; Toshima K; Lairmore TC; Howe JR; Moley JF; Goodfellow P; Wells SA
Hum Mol Genet; 1993 Jul; 2(7):851-6. PubMed ID: 8103403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
